Prophylaxis and treatment of hepatitis B in immunocompromised patients. by Marzano, A. et al.
Digestive and Liver Disease 39 (2007) 397–408
Review Article
Prophylaxis and treatment of hepatitis B in
immunocompromised patients
A. Marzano a,∗, E. Angelucci b, P. Andreone c, M. Brunetto d, R. Bruno e, P. Burra f, P. Caraceni c,
B. Daniele g, V. Di Marco h, F. Fabrizi i, S. Fagiuoli j, P. Grossi k, P. Lampertico l,
R. Meliconi m, A. Mangia n, M. Puoti o, G. Raimondo p, A. Smedile a,
for the Italian Association for the Study of the Liver (A.I.S.F.)
a Division of Gastroenterology and Hepatology, AO San Giovanni Battista, Torino, Italy
b Hematology Division and Haemopoietic Stem Cell Transplant Centre, “Armando Businco” Cancer Centre, Cagliari, Italy
c Department of Internal Medicine, Cardio-Angiology and Hepatology, University of Bologna, Italy
d Division of Gastroenterology and Hepatology, AOU Pisana, Pisa, Italy
e Institute of Infectious and Tropical Diseases, University of Pavia, Italy
f Department of Surgical and Gastroenterological Science, University of Padova, Italy
g Medical Oncology Unit, Ospedale G. Rummo, Benevento, Italy
h Division of Gastroenterology and Hepatology, University of Palermo, Italy
i Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS, Milan, Italy
j Division of Gastroenterology, Ospedali Riuniti, Bergamo, Italy
k Division of Infectious and Tropical Diseases, Department of Clinical Medicine, University of Insubria, Varese, Italy
l Division of Gastroenterology, IRCCS Maggiore Hospital, University of Milan, Italy
m Immunology and Genetics Laboratory, Istituti Ortopedici Rizzoli, Bologna, Italy
n Division of Gastroenterology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
o Institute of Infectious and Tropical Diseases, University of Brescia, Italy
p Department of Internal Medicine, University of Messina, ItalyReceived 3 May 2006; accepted 18 December 2006
Available online 23 March 2007
Abstract
The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era.
Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition
in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive
use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk,
(d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunosuppression)
in subjects with markers of previous contact with HBV (HBsAg negative and anti-HBc positive), in order to prevent reverse seroconversion.
Moreover it is suggested a strict adherence to criteria of allocation based on the virological characteristics of both recipients and donors
in the general setting of transplants and in liver transplantation the universal prophylaxis with nucleos(t)ides analogues (frequently combined
with specific anti-HBV immunoglobulins) in HBsAg positive candidates and in HBsAg negative recipients of anti-HBc positive grafts.
© 2006 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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. Introduction
Immunosuppression due to the underlying disease or to
rugs used in autoimmune diseases, anticancer therapy and
n organ transplants can influence the hepatitis B virus (HBV),
oth in terms of reactivation and in terms of the acceleration
f a pre-existing chronic hepatitis.
In this situation, the possibility of HBV relapse has
een known for years, with clinical manifestations rang-
ng from self-limiting anicteric to fulminant forms or to
hronic hepatitis with an accelerated clinical course towards
iver decompensation. In most cases, hepatitis B develops
t the time of immune reconstitution as a consequence of
he antiviral immune response and less frequently at the
ime of the enhanced replication during massive immuno-
uppression. Moreover hepatitis reactivation may influence
he continuation of the specific treatments and the survival of
mmunosuppressed or transplanted patients [1].
The risk of clinical events is mainly observed in overt
arriers of HBV, but can also develop in the “occult” condition
f infection which has been widely described in the literature
f the last decade [2].
Progress in the diagnostic procedures of the various viro-
ogical conditions associated with HBV and in particular
he recent availability of effective antiviral treatments has
rought this problem to the fore although it is still debated.
This encouraged the Italian Association for the Study of
he Liver (AISF) to organize a Consensus conference accord-
ng to the Italian Institute of Health guidelines (www.pnlg.it)
Table 1), which was held in Turin on May 13th and 14th,
005. The indications reported below are the conclusions
hich emerged during and after the meeting, from the system-




Persistant HBV infection is defined as overt when the
epatitis B surface antigen (HBsAg) is present in amounts
ell-detectable by sensitive immune assays and occult in
BsAg negative subjects with evidence of intrahepatic and/or
erum HBV DNA [2]. In occult carriers, HBsAg can be
able 1
evels of evidence and degree of substantiation (PNGL, www.pnlg.it)
vidence levels from
RCTs and/or revision of RCTs
I From a single RCT
II From cohort studies with historical controls or their meta-analyses
V From retrospective studies such as case-control studies or their meta-an
Evidence from series of cases without a control group
I Opinion of experts in guidelines or consensus
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ompletely absent or undetectable for very low amounts or
olymorphisms.
.1.1. HBV carriers (HBsAg positive)
In accordance with the international definitions, they can
e identified as: (1) active carriers, in presence of hepati-
is B envelope antigen (HBeAg) or of antibody to HBeAg
anti-HBe) and of a viral load ≥20,000 IU/mL, according to
he most recent standardisations; this condition is associated
ith the presence of hepatic disease in the most part of cases
AIII), or (2) inactive carriers, in case of subjects HBeAg neg-
tive and anti-HBe positive, whose alanine aminotransferase
ALT) levels are persistently within the normal range, HBV
NA below 20,000 IU/mL and antibody to HBcAg (anti-
Bc) IgM levels <0.20 IMx index. In the majority of these
ubjects, the histological finding, when available, does not
eveal a significant liver disease (necroinflammatory score
4 histology activity index (HAI)), while in a small minor-
ty of cases it is possible to observe the effects of a chronic
iver disease which became silent spontaneously or following
ntiviral treatment [3,4] (BIII).
.1.2. Occult HBV carriers (HBsAg negative)
The difficulty in determining HBV DNA in the liver biopsy
frequently not justified in subjects without clinical signs of
epatitis), the rare presence of detectable viremia in serum
ven with sensitive techniques, and the frequent presence in
ccult carriers of markers of previous contact with the HBV
anti-HBc± antibody to HBsAg (anti-HBs)), leads to con-
ider all anti-HBc (anti-core) positive subjects as potential
ccult carriers. Instead there are no serum determinants in
he minority (about 20%) of occult carriers who are negative
or all HBV markers.
.2. Virological events
In HBV carriers (occult or overt), the following viro-
ogical events are considered significant: (1) in anti-core
ubjects the re-emergence of HBsAg (seroreversion) (AIII),
2) in inactive carriers the appearance of a significant
iremia (≥20,000 IU/mL) (reactivation), as this is fre-Degree of substantiation: recommended procedure
A Strongly




3) in active carriers the persistence of a significant
iremia (≥20,000 IU/mL in HBeAg positive patients and
2000 IU/mL in HBeAg negative subjects with chronic
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Table 2
Virological categories
Active carrier Inactive carrier Anti-HBc positive (anti-core)
HBsAg Positive Positive Negative
HBeAg Positive or negative Negative Negative
Anti-HBs Negative Negative Positive or negative
Anti-HBc Positive Positive Positive
HBV DNA serum ≥20,000–2000a IU/mL <20,000 IU/mL Negative (>90%)
ALTb Persistently or intermittently increased Persistently normalc Persistently normalc
HBV DNA tissue Positive Positive Positive
Liver damaged Yes (>90%) No (>90%)c Noc
a In anti-HBe positive patients.
b Alanine aminotransferase.
c In the absence of other causes of chronic hepatitis and/or of a previous history of chronic hepatitis B.
d Necroinflammatory score >4 HAI.
Table 3
Baseline assessment








and/or with chronic hepatitis
Transaminase, gamma-glutamyl
transpeptidase, alkaline phosphatase
Ultrasonography HDV Anti-HBe IgM anti-HBc (IMx index)
































otal and fractionated bilirubin Cholesterol and triglycerides
nti-HCV Prothrombin time
BsAg, anti-HBs titre, anti-HBc Ferritin
epatitis) (activity), as this is frequently associated with pro-
ression of liver damage due to HBV (AIII), (4) in all the
irological categories (whether or not during prophylaxis or
herapy with antivirals), the increase in at least one loga-
ithm of HBV DNA, compared to its nadir, reconfirmed in
wo consecutive serum tests during monitoring (virologic
reakthrough) [4] (AV) Table 2.
.3. Clinical definitions
The assessment of chronic liver disease is the fundamental
vent of the diagnostic picture (baseline) (AIII) (Table 3) and
t requires the use of all the instruments usually utilised in
epatology including, if necessary, trans-cutaneous or trans-
ugular liver biopsy in subjects with coagulation problems
for example patients with blood or kidney diseases).
The baseline diagnosis of the disease is pivotal in the








linical condition Infection Yes
Hepatitis Yes
reatment Therapy
a Infection markers: evidence of HBV DNA or HBsAg in serum in originally negNA
omplications is related to the severity of the underlying liver
isease [5].
In order to standardise the definitions the following terms
ere suggested: (1) infection (not necessarily associated with
eactivation of hepatitis) in the case of the detection of HBV
NA by sensitive HBV assays and/or of HBsAg in patients
n whom these markers were originally negative (AVI), (2)
eactivation of hepatitis B (hepatitis), in the presence of a
ignificant viremia and ALT levels above the upper normal
alue (AVI).
. Treatment strategiesThe term prophylaxis was used to mean treatment with
ntiviral drugs of an inactive or occult infection, with the aim
f preventing hepatitis reactivation. Prophylaxis was defined
s: (1) universal prophylaxis (UP), if it is carried out on the
on
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ntire population potentially at risk (inactive carriers and/or
nti-core) or targeted prophylaxis (TP), if it is subordinate
o the appearance of infection markers (HBV DNA and/or
BsAg) in the absence of hepatitis reactivation (Table 4).
Therapy (T) was understood to mean the treatment of hep-
titis B (i.e. chronic hepatitis in active carriers or hepatitis
eactivation in previously inactive carriers and in anti-core
ubjects who develop the seroreversion).
. Treatment options
In Italy, the following drugs are available at present: inter-
erons, either standard or pegylated (both little tolerated in
he condition of immunosuppression, especially in trans-
lant patients for the potential risk of rejection) and the
ucleos(t)ides analogues (NAs), which include lamivudine
nd adefovir-dipivoxil for those with HBV monoinfec-
ion, with the addition of tenofovir and emtricitabine
or patients with HBV–human immunodeficiency virus
HIV) coinfection. Entecavir will be registered in the next
onths.
Lamivudine, which has a potent antiviral effect, frequently
50–60% at 4 years) induces the selection of lamivudine-
esistant mutants in locus YMDD of the polymerase gene
YMDD). Instead adefovir-dipivoxil and entecavir induce a
ower selection of mutants in monotherapy (0–3% at 1–2
ear and genotypic resistance in 29% at 5 years with ade-
ovir in naı̈ve patients; about 10–20% at 2 years with both
rugs in YMDD-carriers) [4–7]. In carriers of the lamivudine-
esistant variant, the combination of adefovir-dipivoxil and
amivudine can synergically control the selection of the
espective mutants [8].
Data from experiences in liver transplanted and HIV
atients have shown a relation between the original viremia,
he degree of immunosuppression and the selection of
utants during prophylaxis with lamivudine [9,10]. Conse-
uently a careful monitoring of the response to treatment and
f the resistance is suggested in immunosuppressed patients.
. Monitoring
Once NAs therapy or prophylaxis has been started, mon-
toring will essentially be through testing serum HBV DNA
nd ALT levels every 3 months, to assess: (1) response to
reatment (i.e. reduction of HBV DNA, preferably below the
imit of sensitivity of the amplified techniques and ALT nor-
alization) (BV) and (2) drug-resistance, which should be
uspected in the case of virologic breakthrough while on-
reatment, in order to activate an early rescue therapy (AIII)
11]. Resistance can be defined clinically by the virologic
reakthrough [4] but if available a genotypic testing could be
sed in order to better define the different mutations and to
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. Impact on different specialist fields
Data regarding hepatitis B in immunocompromised
atients are very heterogeneous, so the statements reported
ere below required an extensive review of the literature and
he inclusion of expert opinions where information was lack-
ng. As a result there was a strong indication to promote
tudies aimed at defining the natural history of hepatitis B in
hese patients, to assess – also prospectively – different treat-
ent protocols, to promote close cooperation among different
pecialists and, finally, to constantly update the indications.
Of note, in all fields a pre-immunosuppression assess-
ent (baseline) is recommended, in both HBsAg positive
nd negative subjects (AIII–V).
. Oncology, haematology and haematopoietic stem
ell transplantation (HSCT)
.1. Background
During chemotherapy hepatitis B can make its appear-
nce in two different phases: (1) during the treatment, in
elation to the intense bone marrow suppression, which is
ssociated with a strong viral replication and, sometimes,
ith the emergence of a fulminant hepatitis in the form of
brosing cholestasis, (2) after the end of therapy, as during
he immuno-reconstitution phase the immune response can
ring on a reactivation of hepatitis whose clinical course may
e more or less severe depending on the baseline condition
f the liver and other possible factors that may contribute to
he damage.
In oncology, the prevalence of HBsAg positive patients
anges between 5.3% (in Europe) and 12% (in China). In
hese patients, the frequency of clinical HBV reactivation
anges between 20% and 56%, correlating with the use of
teroids, anthracyclines, 5-fluorouracil with some virological
ndicators (presence of HBeAg or of e-minus variants and/or
f a detectable HBV DNA prior to therapy). The clinical
ignificance of relapse has been clearly associated with the
re-chemotherapy liver function, with a mortality of 5–40%.
he reactivation of hepatitis, moreover, influences the contin-
ation of the chemotherapy, inducing its suspension and not
nfrequently posing problems of differential diagnosis with
egard to drug toxicity. Hepatitis B can develop both in active
nd in inactive carriers and it is generally associated with the
eappearance of a significant viremia in the preceding 2–3
eeks.
In haematology, the frequency of HBsAg positive patients
s higher (12.2% in Greece and 8.8% in a recent study
rom Italy) and the risk of reactivation appears to be greater
han in other settings of oncology, depending on the degree
f immunosuppression. In this setting, control of the HBV
nfection assumes great importance in order to prevent HBV-
elated complications, but also so as not to modify a highly
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ostic indicators unfavourably associated with hepatitis B
eactivation are, besides those already cited, hyper-trans-
minasemia and the condition of second or third cycle
ompared to the first [1,12–14].
In haematology, a 21–67% (median 50%) risk of reactiva-
ion has been described, with an average mortality of 20%.
n this setting, the available literature is not clear whether the
everity of hepatitis in HBsAg positive patients is directly due
o the liver damage caused by HBV reactivation or by other
auses (i.e. veno-occlusive disease (VOD), Graft versus Host
isease (GvHD) or multi organ failure (MOF)) and also the
egree of risk in relation to the condition of active or inactive
arrier is not clearly determinable.
The risk would appear to be heightened by the use of
onoclonal antibodies (anti-CD20, anti-CD52), with the
ossibility of hepatitis reactivation (even after a cycle of
–3 months of prophylaxis with lamivudine) at a distance
f 12–36 months from the last administration of these drugs,
articularly in overt carriers, but also in anti-core subjects.
n analogous risk exists in the course of allogeneic HSCT,
s the immuno-suppressive effect in the conditioning phase
s particularly strong and it is amplified by the subsequent
ntirejection therapy, so the risk of hepatitis reactivation
emains throughout the phase of immuno-reconstitution (in
ome cases until 1–2 years from transplantation) [1,15–17].
.2. Experiences in the different virological categories
.2.1. Active HBsAg-carriers
In the onco-haematological setting lamivudine therapy of
hronic hepatitis in active carriers appears to be effective [1].
.2.2. Inactive HBsAg-carriers
The start of lamivudine therapy at the time of the clinical
elapse (hepatitis) in inactive carriers maintains a residual
ortality of 20%, probably in relation to the baseline con-
itions and to the delayed treatment. Instead in retrospective
tudies lamivudine has been shown to be effective in prophy-
axis of hepatitis B (0–9% of hepatitis reactivation compared
o 25–85% in untreated patients) and in the only prospective
tudy hepatitis relapse developed in 5% of treated subjects
nd in 24% of controls. Moreover, in the study the universal
se of lamivudine was better than the TP (activated only at the
ppearance of HBV DNA with a non-amplified technique,
uring bimonthly monitoring), both in terms of survival
nd of hepatitis reactivation (0% versus 53%, P = 0.002)
1,17,18].
.2.3. Anti-core patients (HBsAg negative)
In the oncological setting, there are no data, at present,
or this virological category, which can reach 20–40% in
veragely endemic areas and 70–80% in highly endemic
reas. However, in the haematological setting, out of a
otal of 176 patients described in literature, seroreversion
as been reported in 21 subjects (12%) during conven-
ional chemotherapy, whether or not this was associated withr Disease 39 (2007) 397–408 401
SCT, with percentages of 4–30% during chemotherapy and
4–50% in the course of autologous transplantation.
After autologous HSCT hepatitis B developed in anti-
ore patients later (6–52 months, average 19 months) than
n overt carriers (average 2–3 months) and none of the
atients described died of hepatitis B (in seven cases during
herapy with lamivudine, started at the time of the clinical
elapse). After the reactivation 9 of the 10 patients remained
BsAg positive and 1 lost the HBsAg during follow-up.
nstead, 2 deaths out of 39 subjects with seroreversion have
een reported in literature after allogeneic HSCT and this
ppeared to have been significantly linked to the absence of
rotective antibodies (anti-HBs) in the donor and to GvHD
1].
Recently the introduction in haematologic treatments of
onoclonal antilymphocyte B and T antibodies (anti-CD20
nd anti-CD52), used alone or together with chemotherapy,
as been associated with the signalling of six cases of serore-
ersion in anti-core subjects, in three cases with a fulminant
orm and death of the patients, despite therapy with lamivu-
ine [1].
.3. Statements
. In active carriers, therapy is considered useful to con-
trol the liver disease pre- and post-immunosuppressive
treatments. In HSCT, in particular, the control of the
HBV-related disease permits a more precise diagnosis
and treatment of specific liver complications (GvHD and
VOD). In these patients, antiviral therapy should be con-
tinued lifelong (due to the high risk of relapse after
withdrawal) or at least until the disappearance of HBsAg
in serum. A strict monitoring of mutants should be acti-
vated, in order to prevent hepatitis relapse with rescue
therapy (AIII).
. In the inactive carriers, UP appears to be indicated and
should be continued for the entire phase of chemotherapy,
until at least 6–12 months after the end of the treatment
[18] (BV). The optimal duration of the prophylaxis is still
debated and requires prospective studies. In any case, the
panel recommends monitoring of the viremia after sus-
pension, for the prompt diagnosis and return to treatment
in the case of reactivation.
. In anti-core (HBsAg negative) patients, two different
strategies can be identified:
(a) In oncology or in patients undergoing mild haema-
tological therapies (judged to be at low immunosup-
pressive potential, such as the ABVD of the CHOP 21
days scheme), HBsAg monitoring every 1–3 months
is advised, with the activation of TP or therapy in
the case of seroreversion or hepatitis reactivation,
respectively (BVI). Instead the use of HBV DNA
monitoring for targeted prophylaxis remains contro-
versial, because of the lack of data referred to the
timing and duration of the monitoring and to the
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viremia (i.e. the presence of low levels of serum HBV
DNA in anti-core patients after solid organs trans-
plantation is not constantly associated with hepatitis
relapse) [19] (CV).
(b) In subjects who need to be treated with intense
immunosuppression (chemotherapy with fludarabine,
dose-sense regimes, allogeneic transplant, autolo-
gous myeloablative transplant, induction in acute
leukaemia, use of monoclonal antibodies) UP is pro-
posed. This approach is strongly indicated in the
haematological setting and in patients with signs of a
chronic hepatitis (due to a previous history of HBV-
related disease and/or to other causes of chronic
hepatitis) and/or with a positive serum HBV DNA
and/or positive for anti-HBe antibodies at the baseline
evaluation [20] (CVI). In anti-core subjects, clinical
studies are recommended in the future.
.4. Effects of different virological conditions in donors
D) and recipients (R) of allogeneic-HSCT
. D (HBsAg-/anti-HBs+/anti-HBc±)→ R (HBsAg+). In
the case of transplant from an immunized (anti-HBs posi-
tive) donor to an overt carrier (HBsAg positive) recipient,
two possible scenarios have been described: (a) the chance
of adoptive transfer of immunity with the possible clear-
ance of HBsAg (especially if recipients are treated with
lamivudine), (b) an acute and sometimes fulminant hep-
atitis (in historical series) [1].
. D (HBsAg-/anti-HBs±/anti-core+)→R (HBsAg-/anti-
HBs±/anti-core±). Only few data are available, indicat-
ing that in the case of transplant from an anti-core donor
the risk of seroreversion in the recipient would appear to
be negligible in anti-core positive recipients and greater
in the case of complete negativity for the markers of pre-
vious contact with HBV (naı̈ve), in analogy with what has
been described in the transplant of solid organs [21].
. D (HBsAg+)→R (HBsAg-). In a few studies, transplant
from HBsAg positive donor was associated with hepatitis
in 44–62% of recipients, with generic hepatic mortality
in 33–75% of cases, although the role of HBV in these
clinical events was not well defined. In a historical retro-
spective multicentre study performed in the pre-antiviral
phase, the anti-HBV specific immunoglobulins (HBIG)
were not protective against the transmission of the infec-
tion. In contrast, in a recent study the activation of therapy
with lamivudine in donors and of prophylaxis with the
same antiviral in recipients significantly reduced the HBV-
related hepatitis rate (48% versus 7%, P = 0.002) and
mortality (24% versus 0%, P = 0.01) compared to a his-
torical control group [1]..5. General statements in HSCT
The panel of experts who met in Turin proposed the fol-
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he ongoing treatment:
. Vaccination of the recipient prior to transplant with
accelerated protocols (recombinant vaccine 40 g by
intramuscular route time 0–1–2 months or 0–7–21 days),
especially if he/she is naı̈ve (BIII).
. Vaccination of the donor not immunized prior to trans-
plant, with accelerated protocols (recombinant vaccine
20 g by intramuscular route time 0–1–2 months or
0–7–21 days), in the case of allogeneic HSCT (AV).
. Preferential allocation of anti-core organs to vaccinated
recipients or those with markers of prior contact with HBV
(BV).
. Treatment of the HBsAg positive donor with lamivudine
pre-HSCT in order to reduce infectivity through the reduc-
tion of viremia (preferably below the limit of sensitivity
of an amplified assay) and universal prophylaxis of the
recipient on the day before the transplant (AIV).
. The use of high doses of HBIG (intravenous 10,000 IU)
during infusion of hematopoietic stem cells from overt
carriers (who have been preventively treated with antivi-
rals) in HBsAg negative recipients. There is a lack of data
about the neutralising effect of HBIG in this setting in
the antivirals era, but while awaiting prospective studies
there has been recent evidence in the liver transplanta-
tion setting of a direct correlation between HBV DNA
in serum (now preventively reduced in HBsAg positive
recipients by antivirals) and the neutralizing power of the
immunoglobulins [22] (BVI).
The panel agrees that because of the actual results of the
epatologic and haematologic therapy there is no reason to
eny a HSCT from a HBV positive donor (any form) if the
isk-benefit ratio is in favour of transplantation. Moreover in
he case of a HLA identical family HBV positive member
here is no point in wasting time and resources in searching
or an unrelated donor in the international bone marrow donor
ank.




The incidence of overt carriers of HBsAg among dialysed
atients is 0–7% in developed countries and 10–20% in devel-
ping ones. In these subjects, the frequent normality of the
ransaminase makes clinical judgment difficult, confirming
he fundamental role of the virological markers (quantitative
BV DNA) and of the liver biopsy to distinguish betweenctive and inactive carriers (baseline). In this setting, data
bout the condition of occult carrier among anti-core patients
re scarce and regard the sole presence of viremia in serum,

















































































the use of antivirals before transplant (one single antivi-
ral in the case of wild type virus, combined with a secondA. Marzano et al. / Digestive a
In kidney transplant, the condition of HBsAg carrier can
e estimated in 10–20% of cases and it is associated with a
ignificantly higher risk of death (OR 2.49, 95% CI), indepen-
ent of the viremic condition (active or inactive carrier), and
he chronic hepatitis presents an accelerated course towards
irrhosis (5.3–12%-year), decompensation and hepatocarci-
oma [23,24].
In heart and lung transplant, Italian reports have signalled
BsAg positivity in 2.3–3.7% of recipients. In this setting,
he evolution of the HBV-related disease is accelerated in
ctive carriers and the risk of hepatitis B reactivation post-
ransplant is over 50% in originally inactive subjects. Finally,
he risk of seroreversion post-surgery (de novo hepatitis B) in
BsAg negative/anti-core recipients seems to be lower than
% [25–27].
.2. Clinical experiences in nephrology
No controlled trials for the treatment of HBV with either
nterferon or lamivudine in dialysed patients or in kid-
ey transplants are currently available. Interferon can be
sed to treat dialysed patients with chronic hepatitis B,
ut it is contraindicated in transplanted patients. Short-term
dministration of lamivudine monotherapy is effective but
hen the drug is withdrawn, viremia rebounds and hepatitis
elapses in most cases. Continuous administration of lamivu-
ine monotherapy for 3–4 years is able to obtain long-term
uppression of HBV replication and may prevent the devel-
pment of liver related complications and mortality [28].
econdary treatment failure is caused by the emergence of
MDD which in some patients herald hepatitic flares and
rogression of the liver disease.
.3. Statements in relation to transplant recipients
.3.1. Active carrier
In candidates for kidney, heart or lung transplant the indi-
ation to therapy is confirmed, both in the pre-transplant
with NAs or interferons, when they are tolerated) (BV) and
n the post-transplant phase (only NAs in view of the high
isk of interferon-induced rejection) (AV).
.3.2. Inactive carrier
Pre-transplant and during dialysis there is no indication
or prophylaxis but biochemical and virological monitor-
ng is advised, if the diagnosis has been confirmed by
trict adherence to previously defined criteria. Instead, ther-
py should be used in the re-activated forms (HBV DNA
20,000 IU/mL), especially if associated with significant
iver damage (HAI > 4 and/or signs of fibrotic disease by non-
nvasive methods) (BVI). Post-transplant, instead, there is an
ndication to UP, in relation to the available data on mor-
ality in HBV carriers, independently from their virological
ondition [23] (BV).r Disease 39 (2007) 397–408 403
.3.3. Anti-core recipient
In HBsAg negative and anti-core positive recipients of
idney, heart and lung transplant the presence of subclin-
cal manifestations (low levels of circulating HBV DNA
etectable with amplified techniques post-transplant) with-
ut seroreversion in over 95% of cases [19,23,24,27] has been
ignalled. In this condition, only monitoring of the HBsAg
s required, with the activation of TP or therapy only in the
ase of seroreversion and/or hepatitis, respectively (BV).
.4. Statements in relation to transplant donors
.4.1. Anti-core donors
In the case of kidney, heart or lung allocation from an
BsAg negative/anti-core positive/anti-HBs positive or neg-
tive donor in a HBsAg negative recipient, the risk of hepatitis
appears to be less than 5% [27,29]. The low risk does
ot justify preventive prophylaxis, but only HBsAg monitor-
ng (every 3–6 months and/or in the case of transaminase
ncrease) and the use of targeted prophylaxis or therapy only
n the case of seroreversion (BIV). In analogy to what has
een signalled before the risk connected with the use of anti-
ore positive organs is further reduced by the indications
eported in Section 7.5 (AVI).
.4.2. HBsAg positive donors
In this condition, the risk of transmission of the HBV
nfection is very high in the absence of prophylaxis, espe-
ially from HBeAg positive donors [30]. Recently a report
as signalled the post-transplant control of hepatitis B in
BsAg negative/anti-HBs positive recipients of kidneys
rom HBsAg positive donors (HBeAg and HBV DNA-
egative) while on lamivudine prophylaxis [31]. In Italy,





The risk of post-transplantation hepatitis B is strictly
nfluenced from both recipient and donor virological char-
cteristics:
a) HBsAg positive recipients: in the absence of pre-
and post-operative prophylaxis the risk of post-
transplantation hepatitis B is over 80%. In this condition,one that is active on the mutants, in the condition of
drug resistance with active replication), associated with
HBIG after surgery (combined prophylaxis), is protective
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b) HBsAg negative and anti-core positive recipients: in
absence of prophylaxis the risk of seroreversion after
transplantation (de-novo hepatitis B) is less than 5% from
naı̈ve liver donors and 10–15% from anti-core positive
donors [19,34].
c) HBsAg positive donors: the risk of hepatitis B trans-
mission with a liver from an HBsAg positive donor is
high, as the neutralising effect of HBIG is very low in
this setting and the reappearance of HDV, in coinfected
recipients, is constant. In this particular condition, the
reactivation of hepatitis would appear to be controlled
by the combination of two antivirals in the long term
[35].
In Italy, the transplantation is controlled by the national
uidelines (www.governo.it/GovernoInforma/Dossier/
onatori organi/linee guida.html).
d) HBsAg negative/anti-core positive donors: in this cate-
gory the overall risk of HBV transmission and hepatitis
is high (33–78%), in the absence of prophylaxis, rang-
ing from 70% in naı̈ve to 10–15% in anti-core recipients.
Combined prophylaxis with lamivudine and HBIG con-
trols relapse in nearly all cases, while personalised
prophylaxis with only HBIG or only lamivudine has been
suggested in low-risk recipients (anti-core positive) [34].
Comparative studies are not available in this setting.
.2. Statements in relation to recipients
In all HBsAg positive carriers, there is an indication to UP
ost-surgery according to their original virological condition
AIII):
a) In active carriers, therapy before surgery is indicated
(with one or two antivirals in cases of YMDD mutants),
with the aim of achieving the reduction of HBV DNA
below the limit of sensitive HBV assays (AIII) or at least
below <20,000 IU/mL (BIII), in association with com-
bined prophylaxis (HBIG and one or two antivirals, as
previously reported) in the post-operative period.
b) In inactive carriers, the role of therapy before surgery
remains controversial (BIV) because of the high (>80%)
protective effect of post-transplantation combined pro-
phylaxis (BIII). In these subjects, a preventive reduction
of HBV DNA before surgery might not be necessary, with
regard to the minimal residual risk, but it could be desir-
able in order to save HBIG in the long term after liver
transplantation (AV). Likewise, in subjects with spon-
taneous undetectable viremia (PCR-negative) or with
levels around the limit of detectability (<2000 IU/mL),
especially if coinfected with HDV, the protective power
of just HBIG seems to be very high (AIII). Although also
in this condition the use of the combined prophylaxis
after liver transplantation permits a considerable saving
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c) In HBsAg negative/anti-core positive recipients, in anal-
ogy with what has been described in the other transplants,
albeit in the presence of serum and intra-hepatic evidence
of reinfection by HBV in the post-transplant period, the
risk of seroreversion is practically nil [36,37] and so there
is no indication for any prophylaxis, but only for the
monitoring of HBsAg.
.3. Statements in relation to donors
As indicated by the national guidelines the use of organs
rom HBsAg positive donors should be considered only in
onditions of emergency, avoiding their use in HDV recipi-
nts. The use of UP with two antivirals post-transplant could
ermit the control of hepatitis B recurrence in the long term
BV). Instead the use of livers from HBsAg negative/anti-
ore positive donors justifies the adherence to the indications
eported in the paragraph 7.5 and the activation of UP with
BIG and lamivudine in the case of allocation to naı̈ve recip-
ents (BV) and with only HBIG or only lamivudine (after




Reports regarding the reactivation of HBV in the
heumatology setting are episodic, during the course of
ydroxychloroquine, azathioprine, methotrexate and tumour
ecrosis factor (TNF) inhibitors. The few data available all
efer to active and inactive HBsAg- carriers. Instead reports
n anti-CD20 derive from haematological experience, and
ike in haematology the risk of HBV reactivation in the
heumatology setting would appear to be linked both to
he phase of immuno-suppression and to that of immuno-
econstitution. In the meantime no reactivations have been
eported in the few HBsAg positive rheumatology patients
ndergoing UP with lamivudine during immunosuppressive
herapy [38–41].
In the absence of data, the expert panel has identi-
ed two risk categories with regard to the type and to
he degree of immunosuppression: (a) high risk of HBV
eactivation in patients undergoing the following ther-
py: anti-TNF antibodies, medium to high dosage steroids
>7.5 mg/die) for prolonged periods [42], immunosuppres-
ors such as cyclophosphamide, methotrexate, leflunomide,
alcineurin antagonists, azathioprine and mycophenolate
ofetil. Although cases of viral reactivation have not yet
een described in rheumatology patients undergoing treat-
ent with anti-CD20 antibodies, the data which has emergedn other specialist circles suggest the inclusion in this group
f these and other monoclonals (BVI); (b) low risk of HBV
eactivation in patients treated with steroids at <7.5 mg/die,
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0.2. Statements
Among HBsAg positive patients therapy is indicated in
ctive carriers (AVI) and UP with NAs is suggested in
nactive carriers who underwent high-risk treatments, espe-
ially if they are subjects with manifestations of chronic
iver disease due to the previous activity of HBV or other
auses (BVI). Finally, in inactive HBsAg-carriers treated with
ow-risk therapies and in HBsAg negative/anti-core positive
ubjects the proposal is a strategy of monitoring, with the
ctivation of therapy or TP in the case of viral reactivation
HBV DNA ≥20,000 IU/mL) or seroreversion, respectively
BVI).
Prophylaxis should be started 2–4 weeks before the
mmunosuppressive therapy if possible and continued for
t least 6–12 months afterwards (i.e. after immunosuppres-
ive therapy has been suspended). Haematology literature
dvises particular caution in suspending prophylaxis, espe-
ially in subjects treated with repeated cycles of monoclonal
ntibodies.
0.3. Peculiar conditions in the rheumatology setting
0.3.1. Anti-HBV vaccination
Vaccination in rheumatology patients remains controver-
ial and its cost/benefit ratio should be carefully assessed
n groups particularly at risk of HBV (for example
hose living with HBsAg positive individuals or health
orkers).
0.3.2. Panarteritis nodosa (PAN)
This is a rare necrotising vasculitis that interests small
nd medium-sized arteries which presents, at least in a por-
ion of cases, a pathogenic correlation with HBV infection. In
he treatment of HBV-related PAN, the immunosuppressive
herapy (which also poses the question of an uncontrolled
ctivation of the virus) should be associated with an antivi-
al therapy (in active carriers) or UP (in inactive carriers)
o repress viral replication. In this regard, single cases and
bservational studies with small numbers of cases have doc-




The indications in this setting, refer to the recently pub-
ished European Association for the Study of the Liver
EASL) guidelines. Cirrhosis and liver cancer are the sec-
nd cause of death worldwide in HIV carriers (3–4 million),
% of whom have HBV infection. Coinfection with HIV
ncreases the rate of chronic HBV infection, reduces the
nnual rate of seroconversion to anti-HBe and to anti-HBs
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ion in HBsAg negative subjects in the presence of severe
mmuno-depletion. Moreover, co-infection with HIV acceler-
tes progression towards cirrhosis and liver decompensation
nd reduces survival in decompensated cirrhotics. Therefore,
ortality due to liver disease in those co-infected with HIV-
BV is higher compared to subjects with just HBV infection
43,44].
1.2. Statements
1.2.1. Patients undergoing antiretroviral viral therapy
ART)
In active and inactive carriers, therapy and UP with antivi-
als (utilising the same nucleos(t)ides effective on HBV used
n the treatment of HIV infection) are indicated, respectively
AIII).
In HBsAg negative/anti-core positive subjects, the condi-
ion of occult carrier, characterised by HBV DNA positivity
n serum and/or in the liver, has been identified in 35–90%
f subjects with HIV coinfection using high sensitivity tech-
iques, and only in 1% of cases with less sensitive techniques.
ven in the presence of anecdotal reports of reactivation dur-
ng immunodepletion and/or of suspension of lamivudine,
he risk of seroreversion appears to be very low (0.23/100
atients/year) and it does not therefore justify any prophylaxis
ut only monitoring [44] (BVI).
1.2.2. Patients who do not require ART
In active carriers, therapy with interferons or antivirals is
ndicated. In these subjects, treatment should preferably be
dministered using drugs which do not have any effect on
IV and which do not, in the future, induce resistance to
RT (interferons, entecavir, telbivudine) (AIII).
Instead, in inactive carriers and in anti-core subjects
onitoring of HBV DNA or HBsAg, respectively, is rec-
mmended, with activation of therapy or TP in the case of
eroreversion (BVI).
2. Conclusions
The literature on hepatitis B in immunosuppressed
atients is heterogeneous. It refers mainly to the pre-analogue
ucleos(t)ides era and the period prior to the introduction of
he modern techniques of determination and quantification of
he viremia, which raises many doubts and difficulties about
he interpretation of the studies and leaves several aspects still
matter of debate. This encourages the proposal of a network
f communication between different specialists involved,
n order to better define the natural history, the potential
isk of hepatitis B and the results of the various strategies
roposed.
Even in the light of such premises today it appears to
e justified to propose a rational approach to the problem of
epatitis B in immunocompromised patients (Table 5), which
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Table 5
Prophylaxis and therapy in immunocompromised subjects
Active carrier Inactive carrier Anti-core
HBsAg positive HBsAg negative
Haematology and HSCT T UP UPa High risk
Monitoring low risk
Oncology T UP Monitoring
Solid organ transplant T UP Monitoring
Nephrology (dialysis) T Monitoring Monitoring
Rheumatology T UP (high risk)b Monitoring
Monitoring (low risk)c
HIV T (ART- and ART+) Monitoring (ART−) Monitoring
UP (ART+)
Liver transplantation Td (pre-LT) → UPd (post-LT) UPd,e (pre-LT if PCR+) → UPd,e post-LT Monitoring
ART: antiretroviral therapy, T: therapy, UP: universal prophylaxis, TP: targeted prophylaxis, Monitoring: periodic checking of marker of infection in order to
activate targeted prophylaxis or therapy in anti-core or inactive carriers, respectively, with signs of infection and/or hepatitis B reactivation.
a High risk: chemotherapy with fludarabine, dose-sense regimes, allogeneic transplant, autologous myeloablative transplant, induction in acute leukaemia,
use of monoclonal antibodies (anti-CD20, anti-CD52).
b Immunosuppression therapy (high risk): antiTNF antibodies, medium to high dosage steroids (>7.5 mg/die) for prolonged periods, cyclophosphamide,
methotrexate, leflunomide, calcineurin antagonists, azathioprine and mycophenolate mofetil.
c Immunosuppression therapy (low risk): steroids <7.5 mg/die, sulfasalazine and hydroxychloroquine.
d Lamivudine in naı̈ve, associated with adefovir-dipivoxil in lamivudine-resistant patients.


















monitoring the markers of the HBV in all subjects starting
immunosuppressive therapies and the evaluation of their
liver condition (baseline);
therapy of active carriers;
prophylaxis of inactive carriers, especially if they are
undergoing immunosuppressive therapies judged to be at
high risk. In this case, the treatment should be limited to
the period of immunosuppression and to the subsequent
reconstitution, in the settings in which this is possible
(haematology and HSCT, rheumatology, oncology, HIV)
and continued indefinitely in the condition of solid organs
transplantation;
biochemical and HBsAg monitoring (or viremia monitor-
ing, when this strategy is chosen) with the aim of activating
a swift therapy or a targeted prophylaxis, respectively in
inactive carriers and in anti-core subjects not undergoing
prophylaxis;
evaluation, in the transplant setting, of the virological char-
acteristics of both recipients and donors, in order to activate
the best prophylactic strategies and to obtain the best allo-
cation in the case of a significant risk of hepatitis B after
surgery (organs from donors who are positive for HBsAg
or anti-core antibodies).
Finally, the greatest uncertainty regards the most cost-
ffective management of HBsAg negative/anti-HBc positive
anti-core) subjects. For most of these patients involved in the
ifferent settings, a simple monitoring of HBsAg seems to be
he most rational approach. In contrast, in those enlisted for
SCT and/or undergoing intense chemotherapy, especially
n the presence of multicycles of anti-CD20 or anti-CD52onoclonal antibodies, UP is considered to be cost-effective
nd is therefore proposed. However, clinical studies in this
etting are scarce and there is an absolute need for these to
e conducted in the near future.
Practice points
• Evaluation of liver condition (baseline) and
monitoring of HBV markers and viremia
in all subjects starting immunosuppressive
therapies and/or treated with antivirals for
prophylaxis or therapy of hepatitis B.
• Therapy of active carriers.
• Prophylaxis of inactive carriers and of anti-
core patients in the haematologic setting,
especially if they are undergoing immuno-
suppressive therapies judged to be at high
risk.
• Monitoring of HBV markers in anti-core sub-
jects not undergoing prophylaxis.
• Evaluation, in the transplant setting, of the
virological characteristics of both recipients
and donors, in order to activate the best pro-
phylactic strategies and to obtain the best
allocation in the case of a significant risk of
hepatitis B after surgery.
A. Marzano et al. / Digestive and Live
Research agenda
• Clinical relevance of hepatitis B in overt and
occult (anti-core) HBV carriers undergoing
immunosuppressive therapies.
• Clinical efficacy and relevance of prophylaxis,
therapy or HBsAg monitoring in the different
virological categories and specialist fields.
• Role of mono- or combined-therapy with
different antivirals in patients undergoing
immunosuppressive therapies in terms of
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List of abbreviations
ABVD, Doxorubicine, Bleomycin, Vinblastine, Dacar-
bazine (standard therapy for Hodgkin lymphoma);
anti-core, an HBsAg negative/anti-HBc positive sub-
ject; anti-HBc, antibody to hepatitis B core antigen;
anti-HBe, antibody to hepatitis e antigen; anti-HBs,
antibody to HBsAg; ART, anti-retroviral therapy;
CHOP, Cyclophosphamide, Doxorubicin, Vincristine,
Prednisolone; D, donor; GvHD, Graft versus Host
Disease; HAI, histology activity index; HBeAg, hep-
atitis B envelope antigen; HBIG, anti-HBV specific
immunoglobulins; HBsAg, hepatitis B surface antigen;
HBV, hepatitis B virus; HCV, hepatitis C virus; HDV,
hepatitis D virus; HIV, human immunodeficiency virus;
HSCT, haematopoietic stem cells transplantation; IFN,
interferon; INR, international normal ratio; MOF, multi
organ failure; NAs, nucleos(t)ides analogues; PCR,
polymerase chain reaction; PNLG, Piano Nazionale
Linee Guida (National Guidelines); R, recipient; RCTs,
randomized controlled trials; T, therapy; TNF, tumor
necrosis factor; TP, targeted prophylaxis; UP, univer-
sal prophylaxis; US, ultrasound; VOD, veno-occlusive
disease; YMDD, lamivudine-resistant mutants in locus
YMDD of the polymerase gene.
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